- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- Botensilimab, Balstilimab, Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Michael B. Atkins, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- La Jolla, California • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- Nivolumab 240 mg, Ipilimumab 1mg/kg, Nivolumab 3mg/kg, Nivolumab 360mg
- Drug
- Lead sponsor
- Michael B. Atkins, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more